Syntrix Biosystems


Company News

 
 

Company News for immediate release.

 

Contact:

John A. Zebala, M.D., Ph.D.

President and CEO

253-833-8009
   
Home
Company
Drug Candidates
Research Platforms
Company News
Positions
Contact

 

Patents | Press Releases

 

 

Press Releases

 

 

Syntrix BiosystemsSyntrix Biosystems announces the award from the National Institutes of Health (NIH) supporting Phase 2 clinical testing of Aminopterin in psoriasis

 

Syntrix Biosystems announces the award of a Fast-Track grant from the National Cancer Institute (NCI) to develop a high-resolution optical system for the analysis of cancer tissues

 

Syntrix Biosystems licenses exclusive worldwide rights to NMDA inhibitors for the treatment of antifolate neurotoxicity from the University of Medicine and Dentistry in New Jersey (UMDNJ)

 

Syntrix Biosystems licenses exclusive worldwide rights to Aminopterin from the University of Medicine and Dentistry in New Jersey (UMDNJ)

 

Syntrix Biosystems licenses exclusive wordwide rights to bivalent inhibitors of glutathione S-transferases from the University of Washington

 

Syntrix Biosystems announces the receipt of two Phase I/II Fast-Track Awards from the National Institutes of Health (NIH) and the National Cancer Institute (NCI) to develop high-specificity fluorogenic probes for use in nucleic acid detection and microarrays

 
 
   
 

Syntrix Biosystems, Inc.

215 Clay Street NW, Suite B-5, Auburn, WA  98001

TEL: 253-833-8009 • FAX: 253-833-8127

 

email: info@syntrixbio.com | contact us

© Copyright 2007 Syntrix Biosystems. All Rights Reserved.